Robust Valuations of Life Science Companies, Assets and Licensing Deals

Listen as Stephen Waterman and Kyriakos Tzafestas describe how PharmaVentures’ real-world experience combines with valuation models, in-depth commercial insight including rigorous pricing, and best quality data sources to value companies, assets and pharma licensing deals to give their clients the confidence to negotiate the most robust and defensible positions in deal making to secure the most impactful financial terms.